Repligen (NASDAQ:RGEN) Posts Earnings Results, Beats Expectations By $0.05 EPS

Repligen (NASDAQ:RGEN) posted its earnings results on Tuesday. The biotechnology company reported $0.49 EPS for the quarter, beating the consensus estimate of $0.44 by $0.05, FiscalAI reports. The company had revenue of $197.91 million for the quarter, compared to the consensus estimate of $192.23 million. Repligen had a return on equity of 4.66% and a net margin of 0.25%.The firm’s revenue for the quarter was up 18.1% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.44 earnings per share. Repligen updated its FY 2026 guidance to 1.930-2.010 EPS.

Here are the key takeaways from Repligen’s conference call:

• Repligen finished 2025 strongly with $198M in Q4 and $738M for the year, delivering 16% reported and organic non-COVID growth and beating the high end of prior guidance.
• Franchise momentum was broad-based: proteins and analytics grew >30% in Q4, chromatography >25%, and management highlighted a multi-year upgrade cycle for the SoloVPE PLUS and benefits from the 908 Devices acquisition.
• 2026 guidance expects $810M–$840M revenue (9%–13% organic), ~150 bps operating margin expansion at the midpoint, and adjusted EPS of $1.93–$2.01, signaling continued top-line and margin improvement.
• Key near-term risks include a ~2–3 point headwind from a gene therapy platform, expected tariff surcharges (~50 bps margin impact), and uncertainty from MFN/FDA-related customer capex timing that could damp growth.
• Balance sheet and capital strategy: $768M in cash/marketable securities, an active M&A pipeline (priority for 2026), and continued investments in IT, AI, services and commercial expansion to support future growth.

Repligen Stock Down 0.6%

NASDAQ RGEN opened at $134.65 on Wednesday. The business has a fifty day moving average price of $155.83 and a two-hundred day moving average price of $146.87. The stock has a market capitalization of $7.58 billion, a PE ratio of 6,735.87, a PEG ratio of 2.47 and a beta of 1.13. Repligen has a fifty-two week low of $102.96 and a fifty-two week high of $175.77. The company has a debt-to-equity ratio of 0.26, a current ratio of 8.36 and a quick ratio of 7.14.

Insider Activity at Repligen

In related news, Director Karen A. Dawes sold 275 shares of the company’s stock in a transaction on Wednesday, December 17th. The stock was sold at an average price of $161.00, for a total transaction of $44,275.00. Following the completion of the sale, the director directly owned 91,821 shares in the company, valued at $14,783,181. This represents a 0.30% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 1.20% of the company’s stock.

Institutional Investors Weigh In On Repligen

Hedge funds have recently made changes to their positions in the stock. United Capital Financial Advisors LLC acquired a new position in Repligen during the 3rd quarter worth approximately $368,387,000. Opti Capital Management LP acquired a new position in shares of Repligen during the fourth quarter worth $2,399,209,000. Price T Rowe Associates Inc. MD lifted its stake in shares of Repligen by 31.1% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 4,599,061 shares of the biotechnology company’s stock valued at $753,603,000 after acquiring an additional 1,091,683 shares during the last quarter. RTW Investments LP acquired a new stake in shares of Repligen during the 4th quarter valued at $174,347,000. Finally, Balyasny Asset Management L.P. grew its position in Repligen by 390.6% during the 3rd quarter. Balyasny Asset Management L.P. now owns 767,239 shares of the biotechnology company’s stock worth $102,557,000 after acquiring an additional 610,837 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

RGEN has been the topic of a number of research reports. Wall Street Zen raised Repligen from a “hold” rating to a “buy” rating in a report on Saturday, February 7th. Barclays lifted their price objective on shares of Repligen from $175.00 to $200.00 and gave the stock an “overweight” rating in a research note on Monday, December 15th. Weiss Ratings upgraded shares of Repligen from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Tuesday, February 17th. Wells Fargo & Company lifted their price target on shares of Repligen from $175.00 to $190.00 and gave the company an “overweight” rating in a research report on Monday, December 15th. Finally, UBS Group increased their price target on Repligen from $190.00 to $200.00 and gave the stock a “buy” rating in a research report on Friday, January 16th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $177.92.

Repligen News Roundup

Here are the key news stories impacting Repligen this week:

• Positive Sentiment: Q4 beat on both EPS and revenue with solid year-over-year top-line growth (EPS $0.49 vs $0.44 est; revenue $197.9M vs ~$192M est), supporting the company’s execution track record. Repligen (RGEN) Tops Q4 Earnings and Revenue Estimates
• Positive Sentiment: Analysts remain constructive: TD Cowen (via TipRanks) kept a Buy rating and $200 price target, arguing the cautious guidance still leaves derisked upside given Repligen’s industry position. Repligen: Cautious 2026 Guidance with Derisked Upside and Premium-Valuation Growth Justifying a Buy Rating
• Positive Sentiment: Management framed the FY2026 outlook as a “confident growth path,” highlighting execution drivers and long-term demand in bioprocessing that support multi-year growth potential. Repligen Signals Confident Growth Path In 2026 Outlook
• Neutral Sentiment: Full call transcript and PR are available for investors who want management detail on drivers, margin outlook and product demand (useful for due diligence). Repligen (RGEN) Q4 2025 Earnings Call Transcript
• Negative Sentiment: FY2026 guidance came in below consensus: EPS guidance of $1.93–$2.01 (consensus ~2.06) and revenue guidance $810M–$840M (consensus ~$822.8M) — the shortfall versus Street estimates is the main driver of today’s negative price action. Repligen Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Guidance
• Negative Sentiment: Market reaction: commentary and analysis point to investor disappointment over the guidance gap as the reason shares have moved lower despite the quarter beat. Why Repligen Corporation’s (RGEN) Stock Is Down 6.43%

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.